Literature DB >> 27914528

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway.

Xing Lv1, Gao-Hong Lv1, Guo-Ying Dai1, Hong-Mei Sun2, Hui-Qin Xu3.   

Abstract

The aim of this study was to investigate the effects of high-advanced glycation end products (AGEs) diet on diabetic vascular complications. The Streptozocin (STZ)-induced diabetic mice were fed with high-AGEs diet. Diabetic characteristics, indicators of renal and cardiovascular functions, and pathohistology of pancreas, heart and renal were evaluated. AGEs/RAGE/ROS pathway parameters were determined. During the experiments, the diabetic mice exhibited typical characteristics including weight loss, polydipsia, polyphagia, polyuria, high-blood glucose, and low-serum insulin levels. However, high-AGEs diet effectively aggravated these diabetic characteristics. It also increased the 24-h urine protein levels, serum levels of urea nitrogen, creatinine, c-reactive protein (CRP), low density lipoprotein (LDL), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in the diabetic mice. High-AGEs diet deteriorated the histology of pancreas, heart, and kidneys, and caused structural alterations of endothelial cells, mesangial cells and podocytes in renal cortex. Eventually, high-AGEs diet contributed to the high-AGE levels in serum and kidneys, high-levels of reactive oxygen species (ROS) and low-levels of superoxide dismutase (SOD) in serum, heart, and kidneys. It also upregulated RAGE mRNA and protein expression in heart and kidneys. Our results showed that high-AGEs diet deteriorated vascular complications in the diabetic mice. The activation of AGEs/RAGE/ROS pathway may be involved in the pathogenesis of vascular complications in diabetes. Copyright Â
© 2016 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AGEs/RAGE/ROS pathway; Advanced glycation end products; Diabetic vascular complications; Reactive oxygen species; c-Reactive protein

Mesh:

Substances:

Year:  2016        PMID: 27914528     DOI: 10.1016/S1875-5364(16)30101-7

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  7 in total

Review 1.  Dietary Advanced Glycation End Products and Cardiometabolic Risk.

Authors:  Claudia Luévano-Contreras; Armando Gómez-Ojeda; Maciste Habacuc Macías-Cervantes; Ma Eugenia Garay-Sevilla
Journal:  Curr Diab Rep       Date:  2017-08       Impact factor: 4.810

Review 2.  The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.

Authors:  Jyotiska Chaudhuri; Yasmin Bains; Sanjib Guha; Arnold Kahn; David Hall; Neelanjan Bose; Alejandro Gugliucci; Pankaj Kapahi
Journal:  Cell Metab       Date:  2018-09-04       Impact factor: 27.287

3.  Content of nitric oxide and glycative compounds in cured meat products-Negative impact upon health.

Authors:  Ya-Chen Yang; Zhi-Hong Wang; Mei-Chin Yin
Journal:  Biomedicine (Taipei)       Date:  2018-05-28

4.  Oxidative Stress and DNA Lesion Reduction of a Polyphenolic Enriched Extract of Thymus marschallianus Willd. in Endothelial Vascular Cells Exposed to Hyperglycemia.

Authors:  Irina Ielciu; Gabriela Adriana Filip; Ilioara Oniga; Neli-Kinga Olah; Ioana Bâldea; Diana Olteanu; Ramona Flavia Burtescu; Violeta Turcuș; Alexandra C Sevastre-Berghian; Daniela Benedec; Daniela Hanganu
Journal:  Plants (Basel)       Date:  2021-12-18

5.  Diabetic nephropathy patients show hyper-responsiveness to N6-carboxymethyllysine.

Authors:  C G Dias; L Venkataswamy; S Balakrishna
Journal:  Braz J Med Biol Res       Date:  2022-07-25       Impact factor: 2.904

Review 6.  NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes.

Authors:  Sachin V Suryavanshi; Yogesh A Kulkarni
Journal:  Front Pharmacol       Date:  2017-11-07       Impact factor: 5.810

7.  Hyperglycemia-related advanced glycation end-products is associated with the altered phosphatidylcholine metabolism in osteoarthritis patients with diabetes.

Authors:  Weidong Zhang; Edward W Randell; Guang Sun; Sergei Likhodii; Ming Liu; Andrew Furey; Guangju Zhai
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.